(Q40358470)

19 September 2017

title

Human parvovirus B19 infection of monocytic cell line U937 and antibody-dependent enhancement (English)

1 reference

19 September 2017

Yasuhiko Munakata

1

1 reference

19 September 2017

Ichiro Kato

2

1 reference

19 September 2017

Takako Saito

3

1 reference

19 September 2017

Takao Kodera

4

1 reference

19 September 2017

Keiko Kumura Ishii

5

1 reference

19 September 2017

Takeshi Sasaki

6

1 reference

19 September 2017

language of work or name

English

0 references

publication date

24 October 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

345

1 reference

19 September 2017

issue

1

1 reference

19 September 2017

page(s)

251-257

1 reference

Experimental parvoviral infection in humans

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Parvovirus B19 in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Erythrocyte P antigen: cellular receptor for B19 parvovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Antibody-Dependent Enhancement of Virus Infection and Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Pathogenesis of dengue: challenges to molecular biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Antibody-enhanced dengue virus infection in primate leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

ENHANCEMENT OF THE INFECTIVITY OF ARBOVIRUSES BY SPECIFIC ANTISERA PRODUCED IN DOMESTIC FOWLS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Fetal brain infection with human parvovirus B19.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Parvovirus B19 infection presenting with necrotizing lymphadenitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Pathogenesis of human parvovirus B19 in rheumatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Spontaneous resolution of hemophagocytic syndrome associated with acute parvovirus B19 infection and concomitant Epstein-Barr virus reactivation in an otherwise healthy adult

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Parvovirus B19 infection and autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Role of soluble cytokines on the restricted replication of poliovirus in the monocytic U937 cell line.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Macrophages are required for influenza virus infection of human lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Antibody-mediated enhancement of rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Antibody-dependent enhancement of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Evaluation of anti-parvovirus B19 activity in sera by assay using quantitative polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Human parvovirus B19 as a causative agent for rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

Aleutian mink disease parvovirus infection of mink macrophages and human macrophage cell line U937: demonstration of antibody-dependent enhancement of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.09.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.09.040

1 reference

19 September 2017

1 reference